Effects of raloxifene on carotid blood flow resistance and endothelium-dependent vasodilation in postmenopausal women

Atherosclerosis

Volumn 167, Issue 1, 2003, Pages 121-127

  Ceresini, Graziano ^a   Marchini, Lorenzo ^a   Rebecchi, Isabella ^a   Morganti, Simonetta ^a   Bertone, Luca ^a   Montanari, Ilaria ^a   Bacchi Modena, Alberto ^a   Sgarabotto, Maria ^a   Baldini, Monica ^a   Denti, Licia ^a   Ablondi, Fabrizio ^a   Ceda, Gian Paolo ^a   Valenti, Giorgio ^a  

^a UNIVERSITY OF PARMA   (Italy)

Author keywords

Carotid arteries; Endothelial function; Menopause; Raloxifene

Indexed keywords

PLACEBO; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ADULT; ARTERY DIAMETER; ARTERY DILATATION; ARTICLE; BLOOD FLOWMETRY; BRACHIAL ARTERY; CAROTID ARTERY FLOW; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN EXPERIMENT; MEASUREMENT; NORMAL HUMAN; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZATION; STIMULATION; STIMULUS RESPONSE; VASCULAR RESISTANCE;

AGED; BLOOD FLOW VELOCITY; CAROTID ARTERIES; CONFIDENCE INTERVALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; ENDOTHELIUM, VASCULAR; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; MIDDLE AGED; POSTMENOPAUSE; PROBABILITY; RALOXIFENE; REFERENCE VALUES; SENSITIVITY AND SPECIFICITY; VASCULAR RESISTANCE; VASODILATION;

EID: 12244268675     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(02)00420-3     Document Type: Article

References (31)

1. Grodstein F., Stampfer M.J., Mason J.E., et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N. Engl. J. Med. 335:1996;435-461.
2. Stampfer M.J., Colditz G.A., Willett W.C., Manson J.E., Rosner B., Speizer F.E., Hennekens C.H. Postmenopausal estrogen therapy and cardiovascular disease: ten-year follow-up from the nurses' health study. N. Engl. J. Med. 325:1991;756-762.
3. Mendelsohn M.E., Karas R.H. The protective effects of estrogen on the cardiovascular system. N. Engl. J. Med. 340:1999;1801-1811.
4. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women, The postmenopausal E/progestin intervention (PEPI) trial, The Writing Group for the PEPI Trial, J. Am. Med. Assoc. 1995;273:199-208.
5. Hulley S., Grady D., Bush T., Furberg C., Herrington D., Riggs B., Vittinghoff E. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. J. Am. Med. Assoc. 280:1998;605-613.
6. Manson J.E., Martin K.A. Postmenopausal hormone-replacement therapy. N. Engl. J. Med. 345:2001;34-40.
7. Osborne C.K., Zhao H.H., Fuqua S.A.W. Selective estrogen receptor modulators: structure, function, and clinical use. J. Clin. Oncol. 18:2000;3172-3186.
8. Clarke C.S., Shofield P.M., Grace A.A., Metcalfe J.C., Kirschenlohr H.L. Tamoxifen effects on endothelial function and cardiovascular risk factors in men with advanced atherosclerosis. Circulation. 103:2001;1497-1502.
9. Herrington D.M., Pusser B.E., Riley W.A., Thuren T.Y., Brosnihan K.B., Brinton E.A., MacLean D.B. Cardiovascular effects of droloxifene, a new selective estrogen receptor modulator in healthy postmenopausal women. Arterioscler. Thromb. Vasc. Biol. 20:2000;1606-1612.
10. Saitta A., Altavilla D., Cucinotta D., et al. Randomized, double blind, placebo-controlled study on effects of raloxifene and hormone replacement therapy on plasma NO concentrations, endothelin-1 levels, and endothelium-dependent vasodilation in postmenopausal women. Arterioscler. Thromb. Vasc. Biol. 21:2001;1512-1519.
11. Grant E.G. Grant E.G., White E.M. Duplex Sonography of the Cerebrovascular System. 1988;37-46 Springer, New York.
12. Gosling R.G., King K.H. Ultrasound angiology. Harcus A.W., Adamson L. Arteries and Veins. 1975;61-70 Churchill Livingstone, Edinburgh.
13. Maulik D. Principles of Doppler signal processing and haemodynamic analysis. Copel J.A., Reed K.L. Doppler Ultrasound in Obstetrics and Gynecology. 1995;1-18 Raven, New York.
14. Celermajer D.S., Sorensen K.E., Gooch V.M., et al. Non-invasive detection of endothelial disfunction in children and adults at risk of atherosclerosis. Lancet. 340:1992;1111-1115.
15. Sorensen K.E., Celermajer D.S., Spiegelhalter D.J., Georgakopoulos D., Robinson J., Thomas O., Deanfield J.E. Non-invasive measurement of human endothelium dependent arterial responses: accuracy and reproducibility. Br. Heart J. 74:1995;22-27.
16. Adams M.R., Robinson J., McCredie R., Seale J.P., Sorensen K.E., Deanfield J.E., Celermajer D.S. Smooth muscle dysfunction occurs independently of impaired endothelium-dependent dilation in adults at risk of atherosclerosis. J. Am. Coll. Cardiol. 32:1998;123-127.
17. Friedwald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin. Chem. 18:1972;499-502.
18. Naessen T., Bakos O. Carotid vascular resistance in long-term estrogen users. Obstet. Gynecol. 97:2001;327-332.
19. Norusis M.J. SPSS-X Advanced Statistic Guide. 1985;McGraw-Hill, New York.
20. Gangar K.F., Vyas S., Whitehead M., Crook D., Meire H., Campbell S. Pulsatility index in internal carotid artery in relation to transdermal estradiol and time since menopause. Lancet. 338:1991;839-842.
21. Jackson S., Vyas S. A double blind, placebo controlled study of postmenopausal oestrogen replacement therapy and carotid artery pulsatility index. Br. J. Obstet. Gynecol. 105:1998;408-412.
22. Darj E., Bakos O., Naessen T., Persson I. Ultrasonographic blood flow measurement in the carotid arteries in postmenopausal women. Gynecol. Obstet. Invest. 47:1999;20-25.
23. Yue T.L., Vickery-Clark L., Louden C.S., et al. Selective estrogen receptor modulator idoxifene inhibits smooth muscle cell proliferation, enhances reendothelialization, and inhibits neointimal formation in vivo after vascular injury. Circulation. 102:(III):2000;281-288.
24. Penotti M., Sironi L., Miglierina L., Farina M., Barletta L., Gabrielli L., Vignali M. The effect of tamoxifen and transdermal 17beta-estradiol on cerebral arterial vessels: a randomized controlled study. Am. J. Obstet. Gynecol. 178:1998;801-805.
25. Setacci C., la Marca A., Agricola E., et al. Effects of the selective estrogen receptor modulator, raloxifene, on carotid artery pulsatility index in postmenopausal women. Am. J. Obstet. Gynecol. 186:2002;832-835.
26. Herrington D.M., Werbel B.L., Riley W.A., Pusser B.E., Morgan T.M. Individual and combined effects of estrogen/progestin therapy and lovastatin on lipids and flow-mediated vasodilation in postmenopausal women with coronary artery disease. J. Am. Coll. Cardiol. 33:1999;2030-2037.
27. Figtree G., Lu Y., Webb C.M., Collins P. Raloxifene acutely relaxes rabbit coronary arteries in vitro by an estrogen receptor-dependent and nitric oxide-dependent mechanism. Circulation. 100:1999;1095-1101.
28. Rahimian R., Laher I., Dube G., Van Breemen C. Estrogen and selective estrogen receptor modulator LY-117018 enhance release of nitric oxide in rat aorta. J. Pharmacol. Exp. Ther. 283:1997;116-122.
29. HRT, but not raloxifene, improves endothelial function. In: Proceedings of the 12th Annual Meetings of the North American Menopause Society. New Orleans, October 4-6, 2001. http://www.medscape.com/reuters/prof/2001 .
30. Mosca L., Collins P., Herrington D.M., et al. Hormone replacement therapy and cardiovascular disease. Circulation. 104:2001;499-503.
31. Barrett-Connor E., Grady D., Sashegyi A., et al. Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (multiple outcomes of raloxifene evaluation) randomized trial. J. Am. Med. Assoc. 287:2002;847-857.